Earnings Preview: Mylan Laboratories EPS, Revenue Expected to Rise from Previous Quarter

Mylan Laboratories MYL releases its next round of earnings this Wednesday, July 27, 2011. Get the latest predictions in Benzinga's essential guide to the company's second quarter earnings report.

Earnings and Revenue:

Analysts are predicting an EPS reading of 45 cents per share and revenues of $1.5 billion. Wall Street will be looking to see how this quarter's numbers compare to the year-ago quarter's positive EPS of 37 cents per share on revenues of $1.37 billion. We'll know on Wednesday whether Mylan Laboratories has managed the estimated 21.6% increase in EPS and 9.5% rise in revenues on a year-over-year basis.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter	Q1	Q4	Q3	Q2
EPS Estimate	$0.44	$0.45	$0.42	$0.38
EPS Actual	$0.44	$0.45	$0.43	$0.37

Stock Performance:

At last check, shares of Mylan Laboratories were trading at $23.39. Shares are up 10.7% year to date. For a full 12 months, the return has risen by 24.9%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.

• Long-term shareholders are already enjoying 12-month gains prior to the announcement

Average Stock Rating:

The average rating by analysts for Mylan Laboratories is a Moderate Buy. The strength of this rating has declined slightly over the past three months.

Competitors:

Looking for a sympathy stock to trade or interested in the performance of other companies in the same sector? Take a look at some of Mylan Laboratories' peers.

• Forest Laboratories FRX: Hold with a $1.04 recent quarter EPS
• Merck & MRK: Moderate Buy with a $0.92 recent quarter EPS
• Novartis AG NVS: Moderate Buy with a $1.47 recent quarter EPS
• Pfizer PFE: Moderate Buy with a $0.60 recent quarter EPS

The medicine-generic drugs company's industry has seen price/earnings growth of 0.6% during the current fiscal year.

Finally, a description of the company's main areas of operation: Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes pharmaceuticals and active pharmaceutical ingredients.

Take Action:

There is your peek into Mylan Laboratories' upcoming earnings numbers, including some competitors to watch around the time of the announcement. Check back in with us after the announcement for a full recap of the announcement. In the meantime, here are some links to explore today.

• To see up-to-date news on Mylan Laboratories, click here
• To see other trading ideas, click here
• To see other company earnings recaps, click here